J. Thomson's Profile

Role	Title	Level	Year	L/R
🐜	Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. 11 auth. J. Nachman, R. Sposto, Philip Herzog, G. Gilchrist, S. Wolden, J. Thomson, ... M. Kadin, P. Pattengale, P. Davis, R. Hutchinson, Keith White	8	2002	8 🐜
🐜	Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin's lymphoma--a report from the Children's Oncology Group. 10 auth. S. Wolden, Lu Chen, K. Kelly, Philip Herzog, G. Gilchrist, J. Thomson, ... R. Sposto, M. Kadin, R. Hutchinson, J. Nachman	7	2012	7 🐜
🐜	Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. 247 auth. S. Danese, J. Colombel, M. Lukáš, J. Gisbert, G. D'Haens, B. Hayee, R. Panaccione, Hyunsoo Kim, W. Reinisch, H. Tyrrell, Y. Oh, S. Tole, A. Chai, Kirsten Chamberlain-James, M. Tang, ... S. Schreiber, N. Aboo, Xavier Aldeguer Manté, M. Allez, S. Almér, R. Altwegg, M. Andreu García, R. Arasaradnam, S. Ardizzone, A. Armuzzi, I. Arnott, G. Aumais, I. Avni-Biron, Peter H Barrow, I. Beales, F. Bermejo San José, Abraham Bezuidenhout, L. Biancone, Michael Blaeker, Stuart Bloom, B. Bokemeyer, F. Bossa, P. Bossuyt, G. Bouguen, Y. Bouhnik, G. Bouma, R. Bourdages, A. Bourreille, C. Boustière, T. Brabec, S. Brand, C. Buening, A. Buisson, G. Cadiot, X. Calvet Calvo, F. Carbonnel, D. Carpio, J. Cheon, N. Chiba, Camelia Chioncel, N. Cimpoeru, M. Clodi, G. Corazza, R. Cosintino, J. Cotter, T. Creed, Fraser Cummings, G. D. de’ Angelis, M. De Maeyer, Milind Desai, É. Désilets, P. Desreumaux, O. Dewit, J. Dinter, E. D. Dobru, T. Douda, D. Dumitrascu, Matthias Ebert, A. Echarri Piudo, M. Elkhashab, C. Eun, B. Feagan, R. Fejes, C. Fidalgo, S. Fishman, B. Flourié, S. Fowler, W. Fries, Csaba Fulop, M. Fumery, Gyula G Kiss, Sonja Gassner, D. Gaya, B. Germanà, L. Gheorghe, Cyrielle Gilletta de Saint Joseph, P. Gionchetti, A. Goldiş, R. Gonçalves, J. Grimaud, T. Gyökeres, H. Hagège, A. Haidar, H. Hartmann, P. Hasselblatt, B. Hayee, X. Hébuterne, Per Hellström, P. Hindryckx, H. Hlavová, F. Hoentjen, S. Howaldt, L. Hrdlička, K. Huh, M. I. Iborra Colomino, F. Ioniță-Radu, P. Irving, J. Jahnsen, B. Jang, J. Jansen, S. Jeon, R. Jover Martinez, P. Juillerat, P. Karlén, A. Kaser, R. Keil, D. Kejariwal, D. Keret, R. Khanna, Dongwoo Kim, D. Kim, Hyo-Jong Kim, J. S. Kim, Kueongok Kim, Kyung-Jo Kim, S. K. Kim, Young-Ho Kim, Jochen Klaus, A. Kohn, V. Kojecky, J. Koo, Robert Kozak, M. Kremer, T. Kristof, F. Kruger, D. Laharie, Adi Lahat-zok, E. Landa, J. Lee, Kang-Moon Lee, K. Lee, Y. Lee, F. Lenze, W. Lim, J. Limdi, J. Lindsay, P. López Serrano, E. Louis, S. Lueth, G. Maconi, F. Mana, S. Mann, J. Mansfield, S. Marchi, Marco Marino, J. Marshall, M. M. Martín Arranz, R. Mateescu, J. Mclaughlin, S. McLaughlin, E. Melzer, J. Mertens, P. Mitruț, T. Molnár, V. Muls, P. Munuswamy, C. Murray, T. Naftali, Visvakuren Naidoo, Yusuf Nanabhay, L. Negreanu, Augustin Nguyen, T. Ochsenkuehn, A. Orlando, Julian Panes Diaz, M. Paritsky, D. Park, Jihye Park, L. Pastorelli, M. Peck‐Radosavljevic, F. Peerani, J. Pérez Gisbert, L. Peyrin-Biroulet, L. Picon, M. Pierik, T. Ponich, F. Portela, M. Prins, I-né Rácz, K. F. Rahman, J. Reimund, M. Reinshagen, X. Roblin, R. Rocca, F. Rogai, G. Rogler, Á. Salamon, E. Salazar, Z. Sallo, S. Samuel, Miquel de los Santos Sans Cuffi, E. Savarino, V. Savarino, G. Savoye, A. Seicean, C. Selinger, David Serra, H. Shim, S. Shin, B. Siegmund, J. Siffledeen, W. Simmonds, J. Šmid, J. Sollano, G. Song, A. Speight, I. Sporea, D. Staessen, G. Stancu, A. Steel, D. Stepek, V. Stoica, A. Sturm, G. Szekely, Teck Kiang Tan, C. Taxonera Samsó, J. Thomson, Michael p. Tichy, G. Tóth, Z. Tulassay, M. Vangeli, M. Varga, A. Vieira, S. Viennot, E. Villa, P. Vítek, H. Vogelsang, P. Vyhnálek, P. Wahab, J. Walldorf, B. Ye, C. Ziady	5	2021	5 🐜
🐜	Phase II study of high‐dose chemotherapy before radiation in children with newly diagnosed high‐grade astrocytoma 20 auth. T. MacDonald, E. Arenson, J. Ater, R. Sposto, H. Bevan, J. Bruner, M. Deutsch, E. Kurczynski, T. Luerssen, P. McGuire-Cullen, ... R. O'brien, N. Shah, P. Steinbok, J. Strain, J. Thomson, Emi Holmes, G. Vezina, A. Yates, P. Phillips, R. Packer	5	2005	5 🐜
🐜	A Phase III Study for the Treatment of Children and Adolescents with Newly Diagnosed Low Risk Hodgkin Lymphoma (HL) 7 auth. F. Keller, J. Nachman, L. Constine, J. Thomson, K. McCarten, Lu Chen, ... C. Schwartz	4	2010	4 🐜
🐜	#416 A randomized phase II trial of high dose alkylating agents plus VP-16 in children with high grade astrocytoma 16 auth. E. Arenson, J. Ater, J. Bank, H. Bevan, J. Bruner, P. Cullen, M. Deutsch, Emi Holmes, T. Luerssen, R. OʼBrien, ... N. Shah, R. Sposto, P. Steinbok, J. Strain, J. Thomson, A. Yates	2	1999	2 🐜
🐜	Intensive Therapy Free Survival (ITFS) for Early-Stage Hodgkin Lymphoma (cHL) Including Chemotherapy and Radiation Therapy (IFRT) for Recurrence after Chemotherapy alone 9 auth. F. Keller, S. Castellino, L. Constine, S. Voss, J. Thomson, C. Dunphy, ... K. McCarten, Lu Chen, C. Schwartz	2	2014	2 🐜
🐢	Small Molecule Modulators of Metabolic Dysfunction as a Therapeutic Strategy For ALS (P10-8.014) D. Kaganovich, J. Thomson	0	2023	0 🐢
🐜	Identification of pathogenic EGFR mutation in plasma cell-free DNA by ultra-deep sequencing in a patient undergoing stereotactic ablative radiotherapy (SABR) for early-stage lung cancer 9 auth. A. Killean, J. Thomson, M. Adamowicz, S. Warlow, Prasun Dutta, A. Oniscu, ... D. McLaren, Iain Phillips, T. Aitman	0	2022	0 🐜